HomeNewsOpinionCOVID-19 | Cashing in on food grain buffer

COVID-19 | Cashing in on food grain buffer

The government’s proactive move to ensure adequate ration supplies during Covid-19 crisis will help FCI to clear its excess stock

May 11, 2020 / 13:12 IST
Story continues below Advertisement

The outbreak of the coronavirus has thrown up an opportunity for the central government to make a virtue of necessity — the pandemic is coming in handy for the overweight national granary to shed some of its flab.

For long, the Food Corporation of India (FCI) is maintaining a stockpile that is way above the buffer norm requirement set for the corporation. While preserving food grain is itself a headache, the bigger worry is the rising cost of maintaining such a huge stock. Higher inventory means higher storage and financing costs for the FCI and a higher food subsidy bill for the Centre.

Story continues below Advertisement

Spooked by the apprehension that the once-in-a-century health crisis may lead to a rush among consumers to hoard essential commodities, the government has proactively decided to increase grain supply through fair price shops, thereby somewhat easing the burden of excess stock on the national granary.

While unveiling the Rs 1.7-lakh crore Pradhan Mantri Garib Kalyan Package on Thursday, finance minister Nirmala Sitharaman announced that the Modi government has decided to provide 80 crore poor people 5 kg wheat or rice and 1 kg of preferred pulses for free every month for the next three months. Though not explicitly mentioned, these 80 crore are the beneficiaries under the National Food Security Act (NFSA) who, at present, get 5 kg of subsidised food grain through ration shops.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show